Clinical Trials Directory

Trials / Completed

CompletedNCT01160315

Efficiency of Gonadotropin-releasing Hormone (GnRH) Agonist in Preventing Chemotherapy Induced Ovarian Failure

A Prospective Open Randomized Trial on the Efficacy of Gonadotropin-releasing Hormone Agonist Depot-Triptorelin- to Prevent Chemotherapy Induced Premature Ovarian Failure in Lymphoma Patients.

Status
Completed
Phase
Phase 2 / Phase 3
Study type
Interventional
Enrollment
118 (actual)
Sponsor
Erasme University Hospital · Academic / Other
Sex
Female
Age
18 Years – 45 Years
Healthy volunteers
Not accepted

Summary

Chemotherapy drugs like alkylating agents are frequently used in various combined regimens to treat neoplastic and benign diseases. These drugs are definitely associated with premature ovarian failure (POF), resulting in an important decrease of the long-term quality of life and an increase of morbidity. A recent study showed that the patients treated by alkylating agents had a 4.52 fold higher risk to lose their ovarian function compared with those who were treated by other agents. The rate of POF after treatment ranged from 40 to 80%, according to the age of the patients and the total doses administered. Young women who experience POF have to face with the prospects of infertility and to consider years of hormonal replacement therapy. The possibility of minimizing gonadal damage by administering of protective therapy during chemotherapy represents an attractive option for these patients. The aim of this study is to evaluate the protective effect on the ovarian function of the gonadotropin-releasing hormone agonist (GnRha) administered concomitantly to alkylating agents. Preliminary data in the literature on animals (rat and monkeys) are promising. Data in human are, however, highly controversial.

Conditions

Interventions

TypeNameDescription
DRUGTriptorelinTriptorelin: intramusculAR injection every 3 months
DRUGNorethisterone acetate5 mg/day per os until during chemotherapy

Timeline

Start date
2002-07-01
Primary completion
2010-06-01
Completion
2015-10-01
First posted
2010-07-12
Last updated
2015-10-30

Locations

15 sites across 3 countries: Belgium, France, Italy

Source: ClinicalTrials.gov record NCT01160315. Inclusion in this directory is not an endorsement.